<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04321980</url>
  </required_header>
  <id_info>
    <org_study_id>OP-101-003</org_study_id>
    <nct_id>NCT04321980</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Measure the Effect of OP-101 After Being Administered Subcutaneous in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Open-Label Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 (Dendrimer N-acetyl-cysteine) After Subcutaneous Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orpheris, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orpheris, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to measure the Safety, Tolerability, and Pharmacokinetics of OP-101 After&#xD;
      Subcutaneous Administration in Healthy Volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 19, 2020</start_date>
  <completion_date type="Actual">May 22, 2020</completion_date>
  <primary_completion_date type="Actual">May 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. A TEAE (treatment-emergent adverse event) was defined as an AE that emerges, having been absent prior to the study, or an AE that worsens in severity after the first dose of the study drug. Serious AE (SAE) was an AE resulting in any of the following outcomes: death; life-threatening adverse event, required hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, or a medically important event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of OP-101</measure>
    <time_frame>Pre-dose, 0.5 hours and 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose</time_frame>
    <description>Cmax: maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time to Reach Maximum Plasma Concentration (Tmax) of OP-101</measure>
    <time_frame>Pre-dose, 0.5 hours and at 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose</time_frame>
    <description>Tmax: time to reach maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of OP-101</measure>
    <time_frame>Pre-dose, 0.5 hours and 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose</time_frame>
    <description>AUC0-last: Area under the concentration versus time curve from time zero to the last quantifiable concentration (Clast).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to 48 Hour Post Dose Time Point (AUC0-48) of OP-101</measure>
    <time_frame>Pre-dose, 0.5 hours and 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose</time_frame>
    <description>Area under the concentration versus time curve from time zero to 48 hour post dose time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Renal Clearance (CLR) for OP-101</measure>
    <time_frame>Pre-dose, 0 to 4, 4 to 8, 8 to 12, 12 to 18, 18 to 24, and 24 to 48 hours post dose</time_frame>
    <description>CLR was defined as renal clearance of the drug from plasma utilizing the AUC and cumulative amount of unchanged study drug excreted into the urine (Ae) to the same duration (as Amount recovered/AUC at 0-48 hours).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Cohort 1 will be administered 4 mg/kg OP-101 as a subcutaneous (SC) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Cohort 2 will be administered 8 mg/kg OP-101 as a SC injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OP-101</intervention_name>
    <description>Subcutaneous injection of OP-101 in healthy volunteers</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is a healthy man or woman age 18 to 65 years, inclusive, at the Screening Visit;&#xD;
&#xD;
          -  Has the ability to understand and sign the written Informed Consent Form (ICF) and&#xD;
             local medical privacy authorization forms, which must be obtained prior to any study&#xD;
             related procedures being completed;&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 32 kg/m2, inclusive;&#xD;
&#xD;
          -  Is in general good health, based upon the results of a medical history assessment,&#xD;
             physical examination, vital signs, and laboratory profile, as judged by the&#xD;
             Investigator;&#xD;
&#xD;
          -  Female subjects of non-childbearing potential must be either surgically sterile&#xD;
             (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy&#xD;
             at least 26 weeks before the Screening Visit) or postmenopausal, defined as&#xD;
             spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone (FSH)&#xD;
             in the postmenopausal range at screening, based on the central laboratory's ranges;&#xD;
&#xD;
          -  Female subjects of childbearing potential (ie, ovulating, premenopausal, and not&#xD;
             surgically sterile) and all male subjects must use a medically accepted contraceptive&#xD;
             regimen (including hormonal contraceptives) during their participation in the study&#xD;
             and for 30 days after the last administration of study drug. Medically accepted&#xD;
             contraceptive methods are defined as those with 90% or greater efficacy;&#xD;
&#xD;
          -  Acceptable methods of contraception for male subjects enrolled in the study include&#xD;
             the following:&#xD;
&#xD;
             • Condoms or surgical sterilization of subject at least 26 weeks before the Screening&#xD;
             Visit (vasectomy);&#xD;
&#xD;
          -  Acceptable methods of contraception for female subjects enrolled in the study include&#xD;
             the following:&#xD;
&#xD;
               -  Surgical sterilization of subject at least 26 weeks before the Screening Visit&#xD;
                  (includes hysterectomy or bilateral tubal ligation, oophorectomy, or&#xD;
                  salpingectomy);&#xD;
&#xD;
               -  Intrauterine device for at least 12 weeks before the Screening Visit;&#xD;
&#xD;
               -  Hormonal contraception (oral, implant, injection, ring, or patch) for at least 12&#xD;
                  weeks before the Screening Visit; or&#xD;
&#xD;
               -  Diaphragm;&#xD;
&#xD;
          -  If male, subjects must agree to abstain from sperm donation through 90 days after&#xD;
             administration of the last dose of study drug;&#xD;
&#xD;
          -  Female subjects may not be pregnant, lactating, or breastfeeding;&#xD;
&#xD;
          -  Female subjects of childbearing potential must have negative result for pregnancy test&#xD;
             at screening and Check-in;&#xD;
&#xD;
          -  Subjects must have a negative test result for hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis C virus antibody (HCVab), and human immunodeficiency virus (HIV) antibody at&#xD;
             screening;&#xD;
&#xD;
          -  Subjects must have an estimated glomerular filtration rate (eGFR) of ≥90 mL/min/1.73m2&#xD;
             at screening;&#xD;
&#xD;
          -  Subjects must have a negative urine test for drugs of abuse (opiates, benzodiazepines,&#xD;
             amphetamines, cannabinoids, cocaine, barbiturates, and phencyclidine), cotinine, and&#xD;
             breath alcohol test at screening and Check-in; and&#xD;
&#xD;
          -  Subjects must be willing and able to abide by all study requirements and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of clinically significant hematologic, renal, endocrine, pulmonary, cardiac,&#xD;
             gastrointestinal (GI), hepatic, psychiatric, neurologic, immunologic, allergic disease&#xD;
             (including multiple or clinically significant drug allergies), or any other condition&#xD;
             that, in the opinion of the Investigator, might significantly interfere with the&#xD;
             absorption, distribution, metabolism, or excretion of study drug, or place the subject&#xD;
             at an unacceptable risk as a participant in this study;&#xD;
&#xD;
          -  History of malignancy (other than successfully treated basal cell or squamous cell&#xD;
             skin cancer);&#xD;
&#xD;
          -  History or presence of an abnormal ECG that, in the opinion of the Investigator, is&#xD;
             clinically significant;&#xD;
&#xD;
          -  Laboratory results (serum chemistry, hematology, coagulation, and urinalysis) outside&#xD;
             the normal range at screening and Check-in and considered clinically significant in&#xD;
             the opinion of the Investigator. Any elevation of aspartate transaminase (AST) and&#xD;
             alanine transaminase (ALT) above the upper limit of normal at screening and/or&#xD;
             Check-in is exclusionary. One retest of an exclusionary laboratory result is allowed&#xD;
             at the discretion of the Investigator;&#xD;
&#xD;
          -  Has had an acute illness considered clinically significant by the Investigator within&#xD;
             30 days prior to screening;&#xD;
&#xD;
          -  History of alcoholism or drug abuse within 2 years prior to screening;&#xD;
&#xD;
          -  Has used any product containing nicotine within 90 days prior to screening or intends&#xD;
             to use any product containing nicotine during the course of the study;&#xD;
&#xD;
          -  Has had any immunizations (live vaccines) in the 4 weeks prior to screening;&#xD;
&#xD;
          -  Has used medications that affect GI motility or gastric emptying; such as&#xD;
             metoclopramide, proton pump inhibitors, and H2 blockers; within 30 days prior to Day&#xD;
             1;&#xD;
&#xD;
          -  Has used any prescription or over-the-counter medication (with exception of&#xD;
             acetaminophen), vitamins/herbal supplements (with the exception of hormonal&#xD;
             contraceptives) within 14 days prior to Day 1;&#xD;
&#xD;
          -  Has used any other study drug within 30 days or 5 half-lives of the drug (whichever is&#xD;
             longer) prior to Day 1;&#xD;
&#xD;
          -  Has lost or donated &gt;450 mL of whole blood or blood products within 30 days prior to&#xD;
             screening;&#xD;
&#xD;
          -  Investigator has reason to believe that the subject may be unable to fulfill the&#xD;
             protocol visit schedule or requirements;&#xD;
&#xD;
          -  Has any finding that, in the view of the Investigator or Medical Monitor, would&#xD;
             compromise the subject's safety requirements; or&#xD;
&#xD;
          -  Is employed by the Sponsor, the Contract Research Organization (CRO), or the study&#xD;
             site (permanent, temporary contract worker, or designee responsible for the conduct of&#xD;
             the study), or is a family member (spouse, parent, sibling, or child) of the Sponsor,&#xD;
             CRO, or study site employee.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <results_first_submitted>March 31, 2021</results_first_submitted>
  <results_first_submitted_qc>May 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2021</results_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT04321980/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT04321980/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 8 participants were enrolled and treated in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: 4 mg/kg</title>
          <description>Participants in Cohort 1 received a single dose of 4 milligram per kg (mg/kg) OP-101 as subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: 8 mg/kg</title>
          <description>Participants in Cohort 2 received a single dose of 8 mg/kg OP-101 as SC injection on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on safety population which included all participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: 4 mg/kg</title>
          <description>Participants in Cohort 1 received a single dose of 4 milligram per kg (mg/kg) OP-101 as subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: 8 mg/kg</title>
          <description>Participants in Cohort 2 received a single dose of 8 mg/kg OP-101 as SC injection on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filipino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. A TEAE (treatment-emergent adverse event) was defined as an AE that emerges, having been absent prior to the study, or an AE that worsens in severity after the first dose of the study drug. Serious AE (SAE) was an AE resulting in any of the following outcomes: death; life-threatening adverse event, required hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, or a medically important event.</description>
        <time_frame>Up to Day 15</time_frame>
        <population>Analysis was performed on safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 4 mg/kg</title>
            <description>Participants in Cohort 1 received a single dose of 4 mg/kg OP-101 as SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 8 mg/kg</title>
            <description>Participants in Cohort 2 received a single dose of 8 mg/kg OP-101 as SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. A TEAE (treatment-emergent adverse event) was defined as an AE that emerges, having been absent prior to the study, or an AE that worsens in severity after the first dose of the study drug. Serious AE (SAE) was an AE resulting in any of the following outcomes: death; life-threatening adverse event, required hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, or a medically important event.</description>
          <population>Analysis was performed on safety population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of OP-101</title>
        <description>Cmax: maximum observed plasma concentration.</description>
        <time_frame>Pre-dose, 0.5 hours and 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose</time_frame>
        <population>Analysis was performed on pharmacokinetic (PK) parameter population which was defined as all participants who received a dose of study drug and had at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 4 mg/kg</title>
            <description>Participants in Cohort 1 received a single dose of 4 mg/kg OP-101 as SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 8 mg/kg</title>
            <description>Participants in Cohort 2 received a single dose of 8 mg/kg OP-101 as SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of OP-101</title>
          <description>Cmax: maximum observed plasma concentration.</description>
          <population>Analysis was performed on pharmacokinetic (PK) parameter population which was defined as all participants who received a dose of study drug and had at least 1 PK parameter.</population>
          <units>microgram per milliliter(mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.473" spread="0.8183"/>
                    <measurement group_id="O2" value="6.640" spread="0.6073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Time to Reach Maximum Plasma Concentration (Tmax) of OP-101</title>
        <description>Tmax: time to reach maximum observed plasma concentration.</description>
        <time_frame>Pre-dose, 0.5 hours and at 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose</time_frame>
        <population>Analysis was performed on PK parameter population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 4 mg/kg</title>
            <description>Participants in Cohort 1 received a single dose of 4 mg/kg OP-101 as SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 8 mg/kg</title>
            <description>Participants in Cohort 2 received a single dose of 8 mg/kg OP-101 as SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Time to Reach Maximum Plasma Concentration (Tmax) of OP-101</title>
          <description>Tmax: time to reach maximum observed plasma concentration.</description>
          <population>Analysis was performed on PK parameter population.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.015" lower_limit="10.00" upper_limit="16.05"/>
                    <measurement group_id="O2" value="16.000" lower_limit="12.00" upper_limit="24.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of OP-101</title>
        <description>AUC0-last: Area under the concentration versus time curve from time zero to the last quantifiable concentration (Clast).</description>
        <time_frame>Pre-dose, 0.5 hours and 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose</time_frame>
        <population>Analysis was performed on PK parameter population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 4 mg/kg</title>
            <description>Participants in Cohort 1 received a single dose of 4 mg/kg OP-101 as SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 8 mg/kg</title>
            <description>Participants in Cohort 2 received a single dose of 8 mg/kg OP-101 as SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of OP-101</title>
          <description>AUC0-last: Area under the concentration versus time curve from time zero to the last quantifiable concentration (Clast).</description>
          <population>Analysis was performed on PK parameter population.</population>
          <units>hr*mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.940" spread="51.8190"/>
                    <measurement group_id="O2" value="212.325" spread="30.6459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to 48 Hour Post Dose Time Point (AUC0-48) of OP-101</title>
        <description>Area under the concentration versus time curve from time zero to 48 hour post dose time point.</description>
        <time_frame>Pre-dose, 0.5 hours and 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose</time_frame>
        <population>Analysis was performed on PK parameter population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 4 mg/kg</title>
            <description>Participants in Cohort 1 received a single dose of 4 mg/kg OP-101 as SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 8 mg/kg</title>
            <description>Participants in Cohort 2 received a single dose of 8 mg/kg OP-101 as SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to 48 Hour Post Dose Time Point (AUC0-48) of OP-101</title>
          <description>Area under the concentration versus time curve from time zero to 48 hour post dose time point.</description>
          <population>Analysis was performed on PK parameter population.</population>
          <units>hr*mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.705" spread="16.9069"/>
                    <measurement group_id="O2" value="222.173" spread="12.4690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Renal Clearance (CLR) for OP-101</title>
        <description>CLR was defined as renal clearance of the drug from plasma utilizing the AUC and cumulative amount of unchanged study drug excreted into the urine (Ae) to the same duration (as Amount recovered/AUC at 0-48 hours).</description>
        <time_frame>Pre-dose, 0 to 4, 4 to 8, 8 to 12, 12 to 18, 18 to 24, and 24 to 48 hours post dose</time_frame>
        <population>Analysis was performed on PK parameter population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 4 mg/kg</title>
            <description>Participants in Cohort 1 received a single dose of 4 mg/kg OP-101 as SC injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 8 mg/kg</title>
            <description>Participants in Cohort 2 received a single dose of 8 mg/kg OP-101 as SC injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Renal Clearance (CLR) for OP-101</title>
          <description>CLR was defined as renal clearance of the drug from plasma utilizing the AUC and cumulative amount of unchanged study drug excreted into the urine (Ae) to the same duration (as Amount recovered/AUC at 0-48 hours).</description>
          <population>Analysis was performed on PK parameter population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>liter per hour (L/hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.175" spread="0.0354"/>
                    <measurement group_id="O2" value="0.150" spread="0.0606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 15</time_frame>
      <desc>Analysis was performed on safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: 4 mg/kg</title>
          <description>Participants in Cohort 1 received a single dose of 4 mg/kg OP-101 as SC injection on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2: 8 mg/kg</title>
          <description>Participants in Cohort 2 received a single dose of 8 mg/kg OP-101 as SC injection on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site pallor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey L Cleland, PhD, Executive Chair</name_or_title>
      <organization>Orpheris, Inc.</organization>
      <phone>650-505-5048</phone>
      <email>cleland@orpheris.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

